Résultats de la recherche
10
Tout
Rechercher les filtres
Organisation
Fortress Biotech, Inc.
Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform
17 mars 2025 08h55 HE
|
Fortress Biotech, Inc.
FRANKFURT, Germany and MIAMI, March 17, 2025 (GLOBE NEWSWIRE) -- Partex NV and Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company, today announced a...
Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT
27 janv. 2025 08h30 HE
|
Fortress Biotech, Inc.
Study is the first randomized, controlled trial examining a vaccine’s effectiveness in controlling CMV in recipients of HSCT from vaccinated donors Encouraging pilot study results demonstrated the...
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease
06 janv. 2025 08h00 HE
|
Fortress Biotech, Inc.
Priority review granted for CUTX-101 with PDUFA target action date set for June 30, 2025 Cyprium is eligible to receive royalties and up to $129 million in aggregate development and sales milestones ...
Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
14 nov. 2024 16h10 HE
|
Fortress Biotech, Inc.
Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults Cosibelimab PDUFA goal date of December 28 for potential approval to treat metastatic or locally...
Fortress Biotech to Participate in October 2024 Investor Conferences
26 sept. 2024 08h30 HE
|
Fortress Biotech, Inc.
MIAMI, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term...
Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements
20 sept. 2024 08h30 HE
|
Fortress Biotech, Inc.
MIAMI, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on acquiring and advancing assets to...
Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference
04 sept. 2024 08h30 HE
|
Fortress Biotech, Inc.
MIAMI, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term...
Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
13 août 2024 16h05 HE
|
Fortress Biotech, Inc.
PDUFA goal date of November 4, 2024 for DFD-29 for the treatment of inflammatory lesions and erythema of rosacea in adults FDA accepted Biologics License Application resubmission for cosibelimab to...
Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027
25 juil. 2024 08h30 HE
|
Fortress Biotech, Inc.
MIAMI, July 25, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”, or the “Company”), an innovative biopharmaceutical company focused on acquiring and advancing assets to...
Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
05 juil. 2024 16h05 HE
|
Fortress Biotech, Inc.
MIAMI, July 05, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO; FBIOP) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance...